Hedy Kindler to Hematologic Neoplasms
This is a "connection" page, showing publications Hedy Kindler has written about Hematologic Neoplasms.
Connection Strength
0.182
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
Score: 0.182
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.